NASDAQ:CRNX Crinetics Pharmaceuticals Q2 2026 Earnings Report $84.95 0.00 (0.00%) As of 09/1/2026 ProfileEarnings HistoryForecast Crinetics Pharmaceuticals EPS ResultsActual EPS-$1.14Consensus EPS -$1.18Beat/MissBeat by +$0.04One Year Ago EPS-$1.23Crinetics Pharmaceuticals Revenue ResultsActual Revenue$25.12 millionExpected Revenue$14.84 millionBeat/MissBeat by +$10.28 millionYoY Revenue Growth+2,336.90%Crinetics Pharmaceuticals Announcement DetailsQuarterQ2 2026Date8/3/2026TimeAfter Market ClosesConference Call DateMonday, August 3, 2026Conference Call Time4:00PM ETUpcoming EarningsCrinetics Pharmaceuticals' Q3 2026 earnings is estimated for Thursday, November 5, 2026, based on past reporting schedules, with a conference call scheduled at 4:30 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Crinetics Pharmaceuticals Earnings HeadlinesCrinetics Pharmaceuticals, Inc.(NasdaqGS:CRNX) dropped from S&P TMI IndexSeptember 3, 2026 | marketscreener.comMCrinetics Pharmaceuticals, Inc.(NasdaqGS:CRNX) dropped from S&P Global BMI IndexSeptember 3, 2026 | marketscreener.comMMusk says UBI is coming. I say it's already here.Elon Musk says AI could make money irrelevant by 2036. One income program already exists today, funded not by robots but by America's oil and gas infrastructure. It's called the Patriot Income Plan, or P.I.P., and it pays 10% a year across 42 separate distribution dates. This year it's on track to pay out a record 53 billion dollars. Think of it as a personal stake in the world's largest energy producer, structured to deliver income on a regular schedule. | Freedom Financial (Ad)Crinetics Pharmaceuticals, Inc.(NasdaqGS:CRNX) dropped from S&P Pharmaceuticals Select Industry IndexSeptember 3, 2026 | marketscreener.comMVertex Pharmaceuticals Closes Crinetics Pharmaceuticals AcquisitionSeptember 1, 2026 | finance.yahoo.com$HAREHOLDER ALERT: The M&A Class Action Firm Continues To Investigate The Merger—CRNX, PSBQ, D, and NEEAugust 7, 2026 | globenewswire.comSee More Crinetics Pharmaceuticals Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Crinetics Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Crinetics Pharmaceuticals and other key companies, straight to your email. Email Address About Crinetics PharmaceuticalsCrinetics Pharmaceuticals (NASDAQ:CRNX) is a clinical-stage biopharmaceutical company focused on developing orally delivered, nonpeptide therapies for endocrine diseases and other conditions with significant unmet medical needs. The company’s research platform is designed to create selective small-molecule medicines that can act on clinically important hormone receptors. Crinetics’ lead product candidate is paltusotine, an oral somatostatin receptor type 2 agonist being developed for endocrine disorders including acromegaly and carcinoid syndrome. Unlike injectable therapies commonly used in these conditions, paltusotine is intended to provide an oral treatment option. The company is also advancing additional discovery and development programs targeting other endocrine and rare diseases. Founded in 2008, Crinetics is headquartered in San Diego, California, and serves patients and healthcare markets internationally through its research and clinical development activities. The company was co-founded by Scott Struthers, Ph.D., who has served as its president and chief executive officer.View Crinetics Pharmaceuticals ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Aeluma’s Selloff Could Be Setting Up Its Next Big MoveCoreWeave’s Vera Rubin Lead Comes Down to Speed, Power, and ScaleMicron’s New 512GB Memory Module Deepens Its AI Infrastructure AdvantageHoliday Shopping Is Almost Here—And Target May Be Ready to Win BigCan ServisFirst Keep Delivering?Banc of California Bets on Short-Term Pain3 Luxury Consumer Brands to Watch in a Beaten-Down Sector Upcoming Earnings Cintas (9/23/2026)Costco Wholesale (9/24/2026)Micron Technology (9/30/2026)NIKE (10/1/2026)Accenture (10/1/2026)PepsiCo (10/8/2026)Delta Air Lines (10/8/2026)America Movil (10/13/2026)BlackRock (10/13/2026)Citigroup (10/13/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
